Aurinia Pharmaceuticals enters patent settlement pact with Sun Pharmaceutical

Aurinia Pharmaceuticals announced it has entered into a settlement agreement with Sun Pharmaceutical Industries, Sun Pharmaceuticals Industries and Sun Pharma Global FZE that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review, or IPR, directed at Aurinia’s U.S. Patent No. 10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States related to Sun’s Cequa product. Under the settlement agreement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion to terminate the IPR, both parties agreed to dismiss their claims and counterclaims against each other and cease bringing any future further action against the other.